- Price
- $275.19
- Day
- +1.79%
- Mkt Cap
- $39.41B
- 52W Range
- $134.85 – $288.04
- Volume
- 1.88M
- Beta
- 1.50
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that it has submitted an application to Japan's Pharmaceuticals and Medical Devices Agency (PMDA) for approval of the Signatera test in muscle-invasive bladder cancer (MIBC) as a companion diagnostic (CDx). The submission advances Natera's growing presence in Japan, where Signatera received PMDA approval in colorectal cancer in June, becoming the country's first.
Read full article
The company has made massive strides in medical diagnostics and is growing at a rapid clip.
Read full article
Beaconlight Capital LLC increased its holdings in shares of Natera, Inc. (NASDAQ: NTRA) by 44.2% in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 33,589 shares of the medical research company's stock after buying an additional 10,303 shares during the
Read full article
Arrowstreet Capital Limited Partnership raised its position in Natera, Inc. (NASDAQ: NTRA) by 1.0% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,191,732 shares of the medical research company's stock after purchasing an additional 11,793 shares during the quarter. Arrowstreet Capital
Read full article
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the publication of results from a prospective, multicenter study in Merkel cell carcinoma (MCC) published in JAMA Dermatology. The study evaluated the Signatera test against the Merkel cell polyomavirus antibody test (AMERK), finding Signatera to be a significantly stronger predictor of recurrence that also detected relapse earlier.MCC is a rare but aggressive ski.
Read full article
Fifth Third Bancorp boosted its holdings in shares of Natera, Inc. (NASDAQ: NTRA) by 3,373.1% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 11,253 shares of the medical research company's stock after purchasing an additional 10,929 shares during
Read full article
California Public Employees Retirement System lessened its stake in shares of Natera, Inc. (NASDAQ: NTRA) by 23.4% in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 171,151 shares of the medical research company's stock after selling 52,312 shares during the
Read full article
Amova Asset Management Americas Inc. reduced its position in Natera, Inc. (NASDAQ: NTRA) by 10.1% in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 423,424 shares of the medical research company's stock after selling 47,660 shares during the quarter.
Read full article
Stanley Druckenmiller doesn't do consensus. The Duquesne Family Office's latest 13F reveals a top-five long book that skips the mega-cap tech herd almost entirely: a Mexican discount grocer, two biotech names on wildly different trajectories, the one semiconductor stock nobody can ignore, and an Argentine oil producer sitting on a shale reserve about to unlock its first export pipeline.
Read full article
Allspring Global Investments Holdings LLC grew its holdings in Natera, Inc. (NASDAQ: NTRA) by 2.0% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 463,477 shares of the medical research company's stock after purchasing an additional 8,979 shares during the quarter.
Read full article
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today highlighted the impact of a final local coverage determination (LCD) for molecular testing for solid organ allograft rejection: L40060.The LCD strengthens coverage for Prospera in the surveillance settings. The new policy, which is expected to take effect on August 30, 2026, specifically includes:Kidney: 6 tests in year 1; 4 per year in years 2-3. “For-cause” coverage remai.
Read full article
It may not be a familiar name, but Natera has provided better returns than Nvidia over the past 12 months.
Read full article